 Christopher Lieu
Concepts (385)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 47 | 2024 | 751 | 8.850 |
Why?
| | Colonic Neoplasms | 8 | 2024 | 243 | 2.690 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 21 | 2024 | 1565 | 2.250 |
Why?
| | Molecular Targeted Therapy | 9 | 2019 | 390 | 2.030 |
Why?
| | Antineoplastic Agents | 14 | 2021 | 2061 | 1.990 |
Why?
| | Biomarkers, Tumor | 17 | 2025 | 1181 | 1.960 |
Why?
| | Rectal Neoplasms | 7 | 2023 | 136 | 1.770 |
Why?
| | Antibodies, Monoclonal, Humanized | 10 | 2024 | 758 | 1.740 |
Why?
| | Bevacizumab | 5 | 2024 | 129 | 1.690 |
Why?
| | Benzimidazoles | 3 | 2024 | 162 | 1.590 |
Why?
| | Neoplasms | 13 | 2024 | 2469 | 1.260 |
Why?
| | Drug Resistance, Neoplasm | 9 | 2024 | 758 | 1.220 |
Why?
| | Mutation | 14 | 2024 | 3717 | 1.090 |
Why?
| | Age of Onset | 9 | 2024 | 495 | 1.050 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2025 | 72 | 1.010 |
Why?
| | Immunotherapy | 4 | 2022 | 592 | 0.940 |
Why?
| | Neuroendocrine Tumors | 6 | 2024 | 99 | 0.910 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2020 | 529 | 0.890 |
Why?
| | Neoplasm Staging | 12 | 2024 | 1292 | 0.850 |
Why?
| | Cetuximab | 4 | 2023 | 94 | 0.830 |
Why?
| | Oncologists | 1 | 2023 | 35 | 0.830 |
Why?
| | Microsatellite Instability | 8 | 2024 | 37 | 0.830 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 259 | 0.830 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2024 | 212 | 0.790 |
Why?
| | Pancreatic Neoplasms | 8 | 2024 | 881 | 0.790 |
Why?
| | Antibodies, Monoclonal | 6 | 2023 | 1367 | 0.750 |
Why?
| | Humans | 94 | 2025 | 129378 | 0.710 |
Why?
| | Pyrimidinones | 2 | 2024 | 103 | 0.680 |
Why?
| | Pyridones | 2 | 2024 | 158 | 0.640 |
Why?
| | Early Detection of Cancer | 3 | 2024 | 369 | 0.610 |
Why?
| | Colectomy | 1 | 2019 | 94 | 0.600 |
Why?
| | Piperidines | 2 | 2017 | 196 | 0.600 |
Why?
| | Circulating Tumor DNA | 3 | 2025 | 28 | 0.600 |
Why?
| | Middle Aged | 38 | 2024 | 31102 | 0.560 |
Why?
| | Disease-Free Survival | 7 | 2023 | 647 | 0.560 |
Why?
| | Fluorouracil | 6 | 2024 | 199 | 0.560 |
Why?
| | Terminology as Topic | 1 | 2019 | 204 | 0.560 |
Why?
| | Azetidines | 1 | 2017 | 40 | 0.550 |
Why?
| | Genetic Predisposition to Disease | 4 | 2022 | 2281 | 0.550 |
Why?
| | Cyclosporine | 1 | 2018 | 263 | 0.550 |
Why?
| | Appendiceal Neoplasms | 2 | 2020 | 26 | 0.530 |
Why?
| | Aged | 29 | 2024 | 22052 | 0.500 |
Why?
| | Medical Oncology | 5 | 2023 | 272 | 0.500 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 84 | 0.490 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2015 | 71 | 0.480 |
Why?
| | Wnt Signaling Pathway | 2 | 2024 | 170 | 0.480 |
Why?
| | Patient Rights | 1 | 2015 | 11 | 0.480 |
Why?
| | Precision Medicine | 1 | 2019 | 387 | 0.470 |
Why?
| | Therapies, Investigational | 1 | 2015 | 17 | 0.470 |
Why?
| | Drug and Narcotic Control | 1 | 2015 | 28 | 0.470 |
Why?
| | Adult | 34 | 2024 | 35512 | 0.470 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2024 | 381 | 0.470 |
Why?
| | Healthcare Disparities | 1 | 2021 | 578 | 0.470 |
Why?
| | Drugs, Investigational | 1 | 2015 | 32 | 0.470 |
Why?
| | Neovascularization, Pathologic | 2 | 2013 | 297 | 0.450 |
Why?
| | Adenocarcinoma | 5 | 2023 | 896 | 0.430 |
Why?
| | Pyrazines | 2 | 2018 | 86 | 0.420 |
Why?
| | Camptothecin | 4 | 2024 | 109 | 0.410 |
Why?
| | Clinical Trials as Topic | 4 | 2025 | 1004 | 0.410 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 171 | 0.410 |
Why?
| | Immunoglobulin G | 1 | 2017 | 845 | 0.410 |
Why?
| | Microsatellite Repeats | 2 | 2024 | 164 | 0.410 |
Why?
| | Male | 39 | 2024 | 63595 | 0.400 |
Why?
| | Drug Design | 1 | 2013 | 156 | 0.400 |
Why?
| | Leucovorin | 5 | 2024 | 69 | 0.390 |
Why?
| | ErbB Receptors | 5 | 2017 | 607 | 0.390 |
Why?
| | Neoadjuvant Therapy | 5 | 2023 | 383 | 0.380 |
Why?
| | Female | 39 | 2024 | 68686 | 0.380 |
Why?
| | Terminal Care | 1 | 2015 | 235 | 0.370 |
Why?
| | Neoplasm Metastasis | 7 | 2022 | 610 | 0.370 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2011 | 9 | 0.370 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2013 | 328 | 0.360 |
Why?
| | Treatment Outcome | 13 | 2024 | 10195 | 0.350 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 270 | 0.350 |
Why?
| | Imidazoles | 2 | 2024 | 234 | 0.340 |
Why?
| | Fibroblast Growth Factors | 1 | 2011 | 170 | 0.340 |
Why?
| | Clinical Decision-Making | 4 | 2024 | 302 | 0.330 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2024 | 814 | 0.330 |
Why?
| | src-Family Kinases | 1 | 2010 | 96 | 0.320 |
Why?
| | Patient Selection | 3 | 2019 | 662 | 0.310 |
Why?
| | Stomach Neoplasms | 3 | 2022 | 99 | 0.300 |
Why?
| | Disease Management | 4 | 2021 | 586 | 0.300 |
Why?
| | Boronic Acids | 1 | 2008 | 37 | 0.300 |
Why?
| | Janus Kinase 2 | 1 | 2008 | 32 | 0.290 |
Why?
| | Etoposide | 1 | 2008 | 148 | 0.290 |
Why?
| | Carboplatin | 1 | 2008 | 140 | 0.290 |
Why?
| | Myeloproliferative Disorders | 1 | 2008 | 26 | 0.290 |
Why?
| | Health Services Accessibility | 1 | 2015 | 902 | 0.290 |
Why?
| | Genomics | 3 | 2022 | 715 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 6 | 2017 | 857 | 0.280 |
Why?
| | Organoplatinum Compounds | 2 | 2024 | 41 | 0.270 |
Why?
| | Cancer Survivors | 2 | 2024 | 263 | 0.270 |
Why?
| | Carcinoembryonic Antigen | 2 | 2024 | 41 | 0.270 |
Why?
| | Pathology, Molecular | 2 | 2017 | 25 | 0.270 |
Why?
| | Shock, Septic | 1 | 2009 | 208 | 0.270 |
Why?
| | Pathology, Clinical | 2 | 2017 | 36 | 0.270 |
Why?
| | Drug Administration Schedule | 4 | 2019 | 768 | 0.260 |
Why?
| | ras Proteins | 2 | 2017 | 144 | 0.250 |
Why?
| | Age Factors | 5 | 2021 | 3144 | 0.240 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1428 | 0.230 |
Why?
| | Aged, 80 and over | 11 | 2024 | 7069 | 0.230 |
Why?
| | Oximes | 1 | 2024 | 22 | 0.230 |
Why?
| | United States | 13 | 2025 | 13876 | 0.220 |
Why?
| | CD3 Complex | 1 | 2024 | 103 | 0.220 |
Why?
| | Young Adult | 5 | 2024 | 12415 | 0.210 |
Why?
| | Antibodies, Bispecific | 1 | 2024 | 49 | 0.210 |
Why?
| | Metastasectomy | 1 | 2023 | 19 | 0.210 |
Why?
| | Signal Transduction | 6 | 2018 | 4924 | 0.210 |
Why?
| | Trifluridine | 1 | 2022 | 3 | 0.210 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2022 | 72 | 0.210 |
Why?
| | Ovarian Neoplasms | 2 | 2020 | 487 | 0.200 |
Why?
| | Neoplasm Grading | 2 | 2024 | 285 | 0.200 |
Why?
| | Surgical Oncology | 1 | 2022 | 22 | 0.200 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2022 | 93 | 0.200 |
Why?
| | Empathy | 1 | 2024 | 170 | 0.200 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4061 | 0.200 |
Why?
| | Genetic Testing | 3 | 2022 | 428 | 0.190 |
Why?
| | Survival Rate | 6 | 2023 | 1874 | 0.190 |
Why?
| | Membrane Proteins | 3 | 2019 | 1119 | 0.190 |
Why?
| | Incidence | 6 | 2022 | 2641 | 0.190 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2023 | 42 | 0.190 |
Why?
| | Gene Regulatory Networks | 1 | 2024 | 284 | 0.190 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 33 | 0.180 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2022 | 54 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2024 | 245 | 0.180 |
Why?
| | DNA | 1 | 2008 | 1400 | 0.180 |
Why?
| | Pheochromocytoma | 1 | 2022 | 57 | 0.180 |
Why?
| | Meningioma | 1 | 2022 | 81 | 0.180 |
Why?
| | Health Status Disparities | 2 | 2020 | 254 | 0.180 |
Why?
| | Capecitabine | 2 | 2022 | 46 | 0.180 |
Why?
| | Congresses as Topic | 2 | 2019 | 214 | 0.180 |
Why?
| | Heterografts | 1 | 2021 | 131 | 0.170 |
Why?
| | Practice Patterns, Physicians' | 1 | 2009 | 1265 | 0.170 |
Why?
| | Deoxycytidine | 2 | 2024 | 165 | 0.170 |
Why?
| | Immune System | 1 | 2021 | 175 | 0.160 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2019 | 20 | 0.160 |
Why?
| | Area Under Curve | 2 | 2018 | 304 | 0.160 |
Why?
| | Smad4 Protein | 1 | 2019 | 38 | 0.160 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3215 | 0.160 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 81 | 0.160 |
Why?
| | Consensus | 2 | 2019 | 613 | 0.160 |
Why?
| | Retinal Vein | 1 | 2019 | 13 | 0.160 |
Why?
| | Prognosis | 8 | 2023 | 3791 | 0.160 |
Why?
| | GTP Phosphohydrolases | 1 | 2019 | 85 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 511 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2011 | 0.160 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2019 | 31 | 0.150 |
Why?
| | Disease Progression | 4 | 2017 | 2626 | 0.150 |
Why?
| | Vasculitis | 1 | 2019 | 65 | 0.150 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 196 | 0.150 |
Why?
| | Genes, ras | 1 | 2018 | 97 | 0.150 |
Why?
| | DNA Mismatch Repair | 3 | 2024 | 47 | 0.150 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1201 | 0.150 |
Why?
| | Cohort Studies | 6 | 2020 | 5414 | 0.150 |
Why?
| | Retinal Diseases | 1 | 2019 | 86 | 0.150 |
Why?
| | Drug Combinations | 2 | 2022 | 329 | 0.150 |
Why?
| | Risk Factors | 6 | 2022 | 9752 | 0.150 |
Why?
| | Neoplasm Transplantation | 1 | 2018 | 257 | 0.140 |
Why?
| | Survivorship | 1 | 2018 | 48 | 0.140 |
Why?
| | Population Surveillance | 1 | 2021 | 436 | 0.140 |
Why?
| | Risk Assessment | 2 | 2019 | 3236 | 0.140 |
Why?
| | Patient Advocacy | 1 | 2018 | 73 | 0.140 |
Why?
| | Liver Neoplasms | 2 | 2024 | 640 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2019 | 715 | 0.140 |
Why?
| | Acneiform Eruptions | 1 | 2017 | 1 | 0.140 |
Why?
| | Asthenia | 1 | 2017 | 2 | 0.140 |
Why?
| | Drug Eruptions | 1 | 2017 | 27 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 960 | 0.140 |
Why?
| | Hypokalemia | 1 | 2017 | 24 | 0.140 |
Why?
| | Esophageal Neoplasms | 1 | 2021 | 293 | 0.140 |
Why?
| | Patient Compliance | 1 | 2021 | 564 | 0.140 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 45 | 0.140 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 209 | 0.140 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2017 | 76 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 232 | 0.130 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2015 | 375 | 0.130 |
Why?
| | Animals | 10 | 2024 | 35346 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 181 | 0.130 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 8 | 0.130 |
Why?
| | Time Factors | 2 | 2019 | 6550 | 0.130 |
Why?
| | Hospitals | 1 | 2021 | 637 | 0.130 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2018 | 307 | 0.130 |
Why?
| | Biomarkers | 3 | 2023 | 3972 | 0.130 |
Why?
| | Edema | 1 | 2016 | 124 | 0.130 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 197 | 0.130 |
Why?
| | Retrospective Studies | 9 | 2023 | 14498 | 0.130 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 25 | 0.130 |
Why?
| | Databases, Factual | 3 | 2017 | 1269 | 0.130 |
Why?
| | Diabetic Neuropathies | 1 | 2016 | 96 | 0.130 |
Why?
| | GPI-Linked Proteins | 1 | 2016 | 68 | 0.120 |
Why?
| | Patient Care Planning | 1 | 2016 | 149 | 0.120 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 248 | 0.120 |
Why?
| | Device Approval | 1 | 2015 | 21 | 0.120 |
Why?
| | Analgesics | 1 | 2016 | 186 | 0.120 |
Why?
| | Receptor, Notch1 | 1 | 2015 | 61 | 0.120 |
Why?
| | Prevalence | 1 | 2022 | 2560 | 0.120 |
Why?
| | Immunoblotting | 1 | 2015 | 305 | 0.120 |
Why?
| | Quality of Life | 2 | 2024 | 2695 | 0.120 |
Why?
| | Neuralgia | 1 | 2016 | 128 | 0.120 |
Why?
| | Health Behavior | 1 | 2020 | 741 | 0.120 |
Why?
| | Pancreas | 1 | 2017 | 306 | 0.120 |
Why?
| | Administration, Oral | 1 | 2017 | 785 | 0.120 |
Why?
| | Gene Dosage | 1 | 2015 | 142 | 0.120 |
Why?
| | Adolescent | 4 | 2024 | 20378 | 0.120 |
Why?
| | Gene Expression Regulation | 1 | 2024 | 2548 | 0.110 |
Why?
| | Immunoconjugates | 1 | 2016 | 103 | 0.110 |
Why?
| | Drug Approval | 1 | 2015 | 88 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 170 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 937 | 0.110 |
Why?
| | Quinazolines | 1 | 2015 | 244 | 0.110 |
Why?
| | Phenotype | 2 | 2021 | 3076 | 0.110 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 204 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2021 | 893 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2024 | 2344 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 2017 | 637 | 0.110 |
Why?
| | Spinal Cord Injuries | 1 | 2016 | 194 | 0.110 |
Why?
| | beta Catenin | 1 | 2015 | 223 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 769 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1360 | 0.100 |
Why?
| | Registries | 1 | 2021 | 1888 | 0.100 |
Why?
| | Patient-Centered Care | 1 | 2018 | 504 | 0.100 |
Why?
| | National Cancer Institute (U.S.) | 2 | 2025 | 43 | 0.100 |
Why?
| | Lymphocytes | 1 | 2015 | 375 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 891 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 220 | 0.090 |
Why?
| | Risk | 1 | 2014 | 854 | 0.090 |
Why?
| | Ligands | 1 | 2013 | 622 | 0.090 |
Why?
| | Prospective Studies | 3 | 2022 | 7111 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 605 | 0.090 |
Why?
| | Neoplasm, Residual | 2 | 2022 | 120 | 0.090 |
Why?
| | Mice | 5 | 2024 | 16935 | 0.090 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 432 | 0.080 |
Why?
| | Mice, Nude | 2 | 2024 | 683 | 0.080 |
Why?
| | Apoptosis | 3 | 2022 | 2503 | 0.080 |
Why?
| | Streptococcaceae | 1 | 2009 | 2 | 0.080 |
Why?
| | Transcriptome | 1 | 2015 | 887 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1205 | 0.080 |
Why?
| | Patient Satisfaction | 1 | 2013 | 629 | 0.080 |
Why?
| | Cytokines | 2 | 2015 | 2015 | 0.080 |
Why?
| | Clinical Medicine | 1 | 2009 | 21 | 0.080 |
Why?
| | Chemoradiotherapy | 2 | 2023 | 210 | 0.080 |
Why?
| | Myositis | 1 | 2009 | 51 | 0.080 |
Why?
| | Sulindac | 1 | 2008 | 15 | 0.080 |
Why?
| | Bortezomib | 1 | 2008 | 45 | 0.080 |
Why?
| | Mutation Rate | 2 | 2019 | 25 | 0.070 |
Why?
| | Taiwan | 1 | 2008 | 19 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1204 | 0.070 |
Why?
| | Maximum Tolerated Dose | 1 | 2008 | 193 | 0.070 |
Why?
| | Nausea | 1 | 2008 | 108 | 0.070 |
Why?
| | Neutropenia | 1 | 2008 | 134 | 0.070 |
Why?
| | Immunoenzyme Techniques | 1 | 2008 | 213 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1501 | 0.070 |
Why?
| | Fluphenazine | 1 | 2007 | 5 | 0.070 |
Why?
| | Risperidone | 1 | 2007 | 29 | 0.070 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 45 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 1039 | 0.070 |
Why?
| | Anemia | 1 | 2008 | 160 | 0.070 |
Why?
| | Food | 1 | 2008 | 157 | 0.070 |
Why?
| | Exons | 1 | 2008 | 342 | 0.070 |
Why?
| | Gastrectomy | 2 | 2017 | 100 | 0.070 |
Why?
| | Fasting | 1 | 2008 | 267 | 0.070 |
Why?
| | Thrombocytopenia | 1 | 2008 | 186 | 0.060 |
Why?
| | Frontal Lobe | 1 | 2007 | 154 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 265 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2017 | 2479 | 0.060 |
Why?
| | Antipsychotic Agents | 1 | 2007 | 194 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1037 | 0.060 |
Why?
| | Loneliness | 1 | 2024 | 39 | 0.060 |
Why?
| | Survival Analysis | 2 | 2017 | 1272 | 0.060 |
Why?
| | Delayed Diagnosis | 1 | 2024 | 79 | 0.050 |
Why?
| | Oxidative Stress | 1 | 2010 | 1269 | 0.050 |
Why?
| | Natural Language Processing | 1 | 2024 | 94 | 0.050 |
Why?
| | Organoids | 1 | 2024 | 104 | 0.050 |
Why?
| | Paclitaxel | 1 | 2024 | 217 | 0.050 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2022 | 21 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 45 | 0.050 |
Why?
| | Resilience, Psychological | 1 | 2024 | 122 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2022 | 63 | 0.050 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 66 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2022 | 14 | 0.050 |
Why?
| | Radioisotopes | 1 | 2022 | 31 | 0.050 |
Why?
| | Receptors, Peptide | 1 | 2022 | 17 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2022 | 123 | 0.050 |
Why?
| | Intestinal Neoplasms | 1 | 2022 | 28 | 0.050 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2022 | 85 | 0.050 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 38 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2022 | 168 | 0.050 |
Why?
| | Europe | 1 | 2022 | 362 | 0.050 |
Why?
| | North America | 1 | 2022 | 291 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5390 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 31 | 0.050 |
Why?
| | Canada | 1 | 2022 | 347 | 0.040 |
Why?
| | Preventive Medicine | 1 | 2021 | 41 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 67 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 84 | 0.040 |
Why?
| | Liquid Biopsy | 1 | 2020 | 9 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 286 | 0.040 |
Why?
| | Hyaluronic Acid | 1 | 2022 | 213 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 351 | 0.040 |
Why?
| | Geography | 1 | 2020 | 187 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 302 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 231 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 206 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 588 | 0.040 |
Why?
| | Spectrophotometry, Infrared | 1 | 2019 | 54 | 0.040 |
Why?
| | Sulfonamides | 1 | 2022 | 496 | 0.040 |
Why?
| | District of Columbia | 1 | 2018 | 26 | 0.040 |
Why?
| | Karnofsky Performance Status | 1 | 2018 | 38 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 548 | 0.040 |
Why?
| | Colon | 1 | 2020 | 253 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 143 | 0.040 |
Why?
| | Multimodal Imaging | 1 | 2019 | 110 | 0.040 |
Why?
| | Melanoma | 1 | 2024 | 729 | 0.040 |
Why?
| | RNA | 1 | 2024 | 883 | 0.030 |
Why?
| | Half-Life | 1 | 2017 | 162 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 187 | 0.030 |
Why?
| | American Medical Association | 1 | 2017 | 16 | 0.030 |
Why?
| | Genome, Human | 1 | 2019 | 393 | 0.030 |
Why?
| | Delphi Technique | 1 | 2018 | 222 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1706 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2024 | 3079 | 0.030 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 211 | 0.030 |
Why?
| | Genomic Instability | 1 | 2017 | 48 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 210 | 0.030 |
Why?
| | Needles | 1 | 2016 | 57 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 398 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2024 | 2391 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 264 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 129 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1620 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2017 | 169 | 0.030 |
Why?
| | Retreatment | 1 | 2016 | 69 | 0.030 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 98 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 79 | 0.030 |
Why?
| | Acute Disease | 1 | 2019 | 978 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 387 | 0.030 |
Why?
| | Platinum | 1 | 2016 | 44 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 23 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 503 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 481 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 573 | 0.030 |
Why?
| | Radiography | 2 | 2016 | 798 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 67 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 3398 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 122 | 0.030 |
Why?
| | Preoperative Care | 1 | 2017 | 337 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 634 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1494 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2016 | 391 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 326 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 747 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1287 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 2870 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 210 | 0.030 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 382 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 455 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2016 | 508 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 857 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2021 | 1170 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1986 | 0.020 |
Why?
| | Skin | 1 | 2016 | 724 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5061 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4888 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1698 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2016 | 2406 | 0.020 |
Why?
| | Lung | 1 | 2023 | 3919 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 2121 | 0.020 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2009 | 24 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2008 | 68 | 0.020 |
Why?
| | Rats | 1 | 2016 | 5497 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2008 | 79 | 0.020 |
Why?
| | Reference Standards | 1 | 2008 | 177 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2008 | 175 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2019 | 2142 | 0.020 |
Why?
| | Infusions, Intra-Arterial | 1 | 1986 | 53 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 5438 | 0.020 |
Why?
| | Hepatic Artery | 1 | 1986 | 59 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 582 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2528 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1945 | 0.020 |
Why?
| | Reference Values | 1 | 2007 | 793 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 524 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2007 | 743 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2007 | 2714 | 0.010 |
Why?
|
|
Lieu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|